Manufacturing Innovation Across New Modalities

The successful outcomes delivered by cell and gene therapies, coupled with the emergence of modalities across nucleic acid therapeutics and microbiomes, pose the next challenge for innovators to make these new modalities available at scale. Faster adoption of emerging cutting-edge development and manufacturing technologies will be vital to success and broad accessibility for patients. In this talk, we review and present key areas of technology innovation that have the potential to reshape how these advanced therapeutics are manufactured at scale.